Solventum Corporation (SOLV)
SOLV's Strong Q1 Signals Turnaround: Is the Stock Worth Betting Now?
Solventum beats Q1 estimates, raises guidance, and powers ahead with transformation despite looming tariff headwinds.
Solventum (SOLV) Just Overtook the 200-Day Moving Average
Solventum (SOLV) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, SOLV broke through the 200-day moving average, which suggests a long-term bullish trend.
Solventum Corporation (SOLV) Q1 2025 Earnings Call Transcript
Solventum Corporation (NYSE:SOLV ) Q1 2025 Earnings Conference Call May 8, 2025 4:30 PM ET Company Participants Amy Wakeham - Senior Vice President of Investor Relations & External Finance Communications Bryan Hanson - Chief Executive Officer Wayde McMillan - Chief Financial Officer Conference Call Participants Patrick Wood - Morgan Stanley Frederick Wise - Stifel, Nicolaus & Company, Inc. Jason Bednar - Piper Sandler & Co. David Roman - Goldman Sachs Group, Inc. Travis Steed - Bank of America Steven Valiquette - Mizuho Securities Operator Good afternoon. My name is Amy [ph] and I will be your conference call operator for today.
Solventum Corporation: Cheap, With Caveats
Solventum Corporation's stock has dropped 20% since February despite beating earnings and revenue expectations in its last two quarterly reports. SOLV operates in four divisions: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration, with a market cap of $11.5 billion. The company recently announced the sale of its Purification and Filtration business to Thermo Fisher at what seems a more than solid price.
Solventum Stock Gains on Q1 Earnings & Revenue Beat, Margins Decline
SOLV's first-quarter earnings showcase strong segmental performance. However, declining margins raise concerns.
Solventum (SOLV) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
Although the revenue and EPS for Solventum (SOLV) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Solventum (SOLV) Tops Q1 Earnings and Revenue Estimates
Solventum (SOLV) came out with quarterly earnings of $1.34 per share, beating the Zacks Consensus Estimate of $1.19 per share. This compares to earnings of $2.08 per share a year ago.
Solventum Q1 Earnings Likely to Reflect Higher Costs & Expenses
SOLV's Q1 performance is likely to have been hurt by below-par revenue growth in several markets, coupled with currency headwinds. Improved pricing might have offset the sales decline.
SOLV vs. DOCS: Which Stock Is the Better Value Option?
Investors looking for stocks in the Medical Services sector might want to consider either Solventum (SOLV) or Doximity (DOCS). But which of these two companies is the best option for those looking for undervalued stocks?
Solventum (SOLV) Soars 8.8%: Is Further Upside Left in the Stock?
Solventum (SOLV) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Will Solventum (SOLV) Beat Estimates Again in Its Next Earnings Report?
Solventum (SOLV) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Solventum Partners With SprintRay for Same-Day Dental Restorations
SOLV partners with SprintRay to introduce an innovative solution for same-day dental restorations, enhancing efficiency, precision and patient care in digital dentistry.
